Acute Heart Failure Mortality Predictors in UAE: New Multicenter Meta-Analysis Insights

A groundbreaking multicenter systematic review and meta-analysis published today sheds new light on the clinical outcomes and predictors of in-hospital mortality for patients hospitalized with acute heart failure (AHF) in the United Arab Emirates (UAE) and broader Middle East region. This comprehensive study aggregates data from multiple cohorts, highlighting the urgent need for targeted interventions in a region where cardiovascular diseases are rising rapidly due to lifestyle changes, diabetes prevalence, and aging populations.

Acute heart failure, defined as the sudden or rapid onset of symptoms like shortness of breath, fluid retention, and fatigue due to the heart's inability to pump blood effectively, represents a medical emergency. In the UAE, where non-communicable diseases account for over 70% of deaths, AHF hospitalizations strain healthcare resources, with hospitals like Cleveland Clinic Abu Dhabi and Sheikh Khalifa Medical City reporting increasing cases.

🫀 The Burden of Acute Heart Failure in the Middle East

The Middle East, including the UAE, faces a unique cardiovascular profile. Unlike Western countries where ischemic heart disease dominates, regional etiologies blend coronary artery disease (CAD) with high rates of hypertension and diabetes mellitus (DM). Data from prior registries indicate that AHF patients here are younger on average—mean age 59-66 years—yet present with multiple comorbidities.

Diabetes affects over 50% of AHF patients in UAE cohorts, exacerbating fluid overload and renal strain. Obesity rates exceed 35% in the adult population, per UAE Ministry of Health reports, fueling metabolic syndrome. Cultural factors, such as high salt intake in traditional diets and sedentary lifestyles amid rapid urbanization, compound risks. This study underscores how these elements drive higher complication rates compared to global averages.

Study Methodology: Rigorous Multicenter Approach

Researchers conducted a systematic review following PRISMA guidelines, searching databases like PubMed, Scopus, and Embase for studies on AHF in the Middle East and UAE from 2010 onward. Five high-quality cohorts met inclusion criteria, encompassing thousands of patients from multicenter registries like Gulf CARE (Gulf aCute hEart failuRe registry), involving UAE University (UAEU) and other institutions.

Data extraction focused on baseline characteristics, treatments, and outcomes. Meta-analysis used random-effects models to pool in-hospital mortality, accounting for heterogeneity (I² statistic). Subgroup analyses explored UAE-specific trends versus other Middle Eastern countries. Risk of bias was assessed via Newcastle-Ottawa Scale, ensuring robust findings.

Patient Profiles: Who Faces Higher Risks?

AHF patients in the study were predominantly male (52.5-69.6%), with mean ages ranging 59-66 years. Hypertension topped comorbidities (60-80%), followed by DM (50-70%) and CAD as primary etiology (40-55%). Reduced left ventricular ejection fraction (LVEF <40%) prevailed in 60-70% of cases, indicating heart failure with reduced ejection fraction (HFrEF) dominance.

• Common precipitants: Non-compliance with medications (25%), infections (20%), arrhythmias (15%).
• Treatment patterns: Loop diuretics (85%), ACE inhibitors/ARBs (70%), beta-blockers (60%). Device therapy low (<10%).

Expatriate vs. Emirati differences emerged, with locals showing higher CAD prevalence due to genetic and lifestyle factors.

In-Hospital Mortality: Alarming Pooled Rates

Individual studies reported 5.0-10.4% in-hospital mortality, with pooled estimate at 6.50% (95% CI: 5.2-7.8%). Heterogeneity was moderate (I²=45%), reflecting varied hospital capabilities. UAE sites mirrored this, around 6-7%, higher than Western 3-5% but lower than some African registries (10-15%).

Readmission at 3 months: 18%; 12 months: 40% cumulative mortality 20%.

Key Predictors of Mortality Unveiled

The meta-analysis pinpointed independent predictors via multivariate odds ratios (OR):

• Advanced age (>70 years): OR 2.1 (95% CI 1.6-2.8)
• Renal dysfunction (eGFR <30 mL/min): OR 3.2 (2.1-4.9)
• Elevated NT-proBNP (>5000 pg/mL): OR 2.8
• Reduced LVEF (<30%): OR 1.9
• Cardiogenic shock: OR 5.4 (highest risk)

These align with R-hf risk score validated in Middle East, incorporating renal function, hemoglobin, and NYHA class.

Global Comparisons and Regional Insights

Compared to REPORT-HF global study (pooled mortality ~4%), Middle East rates are elevated due to delayed presentation and polypharmacy gaps. Gulf CARE, led by UAEU researchers like Dr. Abdulla Shehab, confirmed ischemic HD (53%) as top cause, vs. hypertension globally.

In UAE, expatriate patients had lower mortality (2-4%) vs. Emiratis (5-7%), per ACS studies, linked to younger age and better access. Read the full meta-analysis for forest plots.

Gulf CARE PMC details: Gulf CARE overview.

Implications for UAE Healthcare

UAE's Vision 2031 prioritizes CVD reduction. Findings urge risk stratification tools like R-hf at admission, early renal monitoring, and NT-proBNP screening. Hospitals should enhance multidisciplinary teams, per first UAE Comprehensive Heart Failure Center at Sheikh Tahnoon Bin Mohammed Medical City (2026 certified).

Policy: Expand tele cardiology, diabetes-HF clinics. Economic impact: AHF costs UAE ~AED 2B annually; prevention saves billions.

UAE Universities Driving Cardiovascular Research

UAEU's Department of Cardiology spearheads Gulf registries, training fellows in HF management. Khalifa University integrates AI for predictor modeling. Zayed University explores social determinants. These efforts position UAE as Middle East research hub, fostering jobs in clinical research.

Collaborations with Cleveland Clinic Abu Dhabi boost trials.

Emerging Treatments and Prevention Strategies

SGLT2 inhibitors (e.g., empagliflozin) cut AHF risk 30% in diabetics; GDMT optimization vital. Lifestyle: UAE Fit Nation campaign targets obesity. Step-by-step prevention:

Photo by Marek Studzinski on Unsplash

• Screen high-risk (DM, HTN) annually.
• Early echo for LVEF.
• Device implants for high-risk HFrEF.
• Digital apps for adherence.

Future Outlook: Calls for Action

Ongoing Gulf HFSA-endorsed conference 2026 will build on this. UAE needs national AHF registry. Researchers call for prospective trials on SGLT2 in regionals.

For clinicians: Integrate predictors into protocols. Patients: Monitor weight, meds. UAE's proactive healthcare can lower rates below 5%.